ProBio (Drug Discovery) Overview
- Year Founded
-
2009
- Status
-
Private
- Employees
-
2,038
- Latest Deal Type
-
2ndary - Private
- Latest Deal Amount
-
$219M
- Investors
-
14
ProBio (Drug Discovery) General Information
Description
Manufacturer of biotechnology products and research services designed to accelerate life science research, drug discovery, and biopharmaceutical development. The company offers end-to-end GMP manufacturing for plasmid DNA, viral vectors, mRNA, and antibody drugs, along with process development, analytical testing, and regulatory support, enabling biotechnology and pharmaceutical companies to scale their therapies from clinical trials to commercial supply with consistent quality and compliance.
Contact Information
Website
www.probiocdmo.cnCorporate Office
- Number 28 Yongxi Road, Jiangning Science Park
- Nanjing, Jiangsu 211100
- China
Corporate Office
- Number 28 Yongxi Road, Jiangning Science Park
- Nanjing, Jiangsu 211100
- China
ProBio (Drug Discovery) Timeline
ProBio (Drug Discovery) Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 4. Secondary Transaction - Private | 28-Apr-2025 | $219M | Completed | Generating Revenue | ||
| 3. Later Stage VC (Series C) | 17-Jan-2023 | Completed | Generating Revenue | |||
| 2. Later Stage VC (Series B) | 01-Jul-2022 | $37.3M | $187M | Completed | Generating Revenue | |
| 1. Later Stage VC (Series A) | 14-May-2021 | $150M | $150M | Completed | Generating Revenue |
ProBio (Drug Discovery) Comparisons
Industry
Financing
Details
ProBio (Drug Discovery) Competitors (2)
One of ProBio (Drug Discovery)’s 2 competitors is JOINN Biologics, a Venture Capital-Backed company based in Beijing, China.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| JOINN Biologics | Venture Capital-Backed | Beijing, China | ||||
| Tergus Pharma | Private Equity-Backed | Durham, NC |
ProBio (Drug Discovery) Related Research & Analysis
Explore institutional-grade private market research from our team of analysts.
-
Verticals
ProBio (Drug Discovery) Patents
ProBio (Drug Discovery) Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2026228614-A1 | Biosynthesis device and biosynthesis method | Pending | 29-Apr-2025 | ||
| WO-2026189530-A1 | Method and apparatus for optimizing protein sequence on basis of genetic algorithm, and device and medium | Pending | 14-Mar-2025 | ||
| WO-2026184713-A1 | Vector and method for preparing circular rna | Pending | 07-Mar-2025 | ||
| WO-2026158520-A1 | Spleen-targeted self-replicating rna-lnp and use thereof | Pending | 24-Jan-2025 | ||
| WO-2026092510-A1 | Protein purification device and method | Pending | 30-Oct-2024 |
ProBio (Drug Discovery) Signals
Growth Rate
Growth
Size Multiple
Key Data Points
Similarweb Unique Visitors
Majestic Referring Domains
ProBio (Drug Discovery) Investors (14)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| China Merchants Capital | Asset Manager | Minority | ||
| China Merchants Group | Holding Company | Minority | ||
| Ciit Asset Management | Asset Manager | Minority | ||
| Fenheng Holdings Limited | Corporation | Minority | ||
| GenScript | Corporation | Minority |
ProBio (Drug Discovery) Investments (2)
ProBio (Drug Discovery)’s most recent deal was a Early Stage VC with ACT Therapeutics. The deal was made on 12-Jul-2022.
| Company Name | Deal Date | Deal Type | Deal Size | Industry | Lead Partner |
|---|---|---|---|---|---|
| ACT Therapeutics | 12-Jul-2022 | Early Stage VC | Drug Discovery | ||
| AffyXell Therapeutics | 16-May-2022 | Early Stage VC | Drug Discovery |
ProBio (Drug Discovery) FAQs
-
When was ProBio (Drug Discovery) founded?
ProBio (Drug Discovery) was founded in 2009.
-
Where is ProBio (Drug Discovery) headquartered?
ProBio (Drug Discovery) is headquartered in Nanjing, China.
-
What is the size of ProBio (Drug Discovery)?
ProBio (Drug Discovery) has 2,038 total employees.
-
What industry is ProBio (Drug Discovery) in?
ProBio (Drug Discovery)’s primary industry is Drug Discovery.
-
Is ProBio (Drug Discovery) a private or public company?
ProBio (Drug Discovery) is a Private company.
-
What is the current valuation of ProBio (Drug Discovery)?
The current valuation of ProBio (Drug Discovery) is .
-
What is ProBio (Drug Discovery)’s current revenue?
The current revenue for ProBio (Drug Discovery) is .
-
How much funding has ProBio (Drug Discovery) raised over time?
ProBio (Drug Discovery) has raised $411M.
-
Who are ProBio (Drug Discovery)’s investors?
China Merchants Capital, China Merchants Group, Ciit Asset Management, Fenheng Holdings Limited, and GenScript are 5 of 14 investors who have invested in ProBio (Drug Discovery).
-
Who are ProBio (Drug Discovery)’s competitors?
JOINN Biologics and Tergus Pharma are competitors of ProBio (Drug Discovery).
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process
